### INTRAVENOUS ANTIBIOTIC DOSING FOR ADULT PATIENTS

|  | DOSE (g       | grams)       | INTERVAL (hours)            |                          |            |  |  |  |  |  |
|--|---------------|--------------|-----------------------------|--------------------------|------------|--|--|--|--|--|
| DRUG   | Usual<br>Dose | High<br>Dose | <65y.o.,<br>with<br>CICr>50 | >65y.o.,renal compromise | CICr<10    |  |  |  |  |  |
| Ampicillin<br>(meningitis: 2gms q 4h)                      | 1-2           | 2            | 6                           | 8 (CICr<20)              | 12         |  |  |  |  |  |
| Azithromycin (Zithromax)                                   | 500           |              | 24                          | 24                       | 24         |  |  |  |  |  |
| Aztreonam (Azactam)  | 1             | 2            | 6                           | 12 (CICr<30)             | 24         |  |  |  |  |  |
| Cefazolin (Ancef)  | 1             |              | 8                           | 12 (CICr<30)             | 24         |  |  |  |  |  |
| Cefepime (Maxipime)  | 1             | 2            | 12                          | 24 (CICr<30)             | 24         |  |  |  |  |  |
| Cefotaxime ( <i>Claforan</i> )<br>(meningitis: 3gms q6h)   | 1             | 2            | 8                           | 12 (CICr<20)             | 24         |  |  |  |  |  |
| Ceftazidime (Fortaz)                                       | 1             | 2            | 8                           | 12 (CICr<50)             | 24         |  |  |  |  |  |
| Ceftriaxone ( <i>Rocephin</i> )<br>(meningitis: 2gms q12h) | 1             | 2            | 24                          | 24                       | 24         |  |  |  |  |  |
| Ciprofloxacin (Cipro)                                      | 0.2 - 0.4     |              | 12                          | 24 (CICr<30)             | 24         |  |  |  |  |  |
| Imipenem/Cilastatin ( <i>Primaxin</i> )                    | 0.5 - 1       | 1            | 6                           | 12 (CICr<30)             | 24         |  |  |  |  |  |
| Levofloxacin (Levaquin)                                    | 0.25 - 0.5    |              | 24                          | 48 (CICr<50)             | 48         |  |  |  |  |  |
| Piperacillin/Tazobactam (Zosyn)                            | 3.375         | 4.5          | 6                           | 8 (CICr<30)              | 12         |  |  |  |  |  |
| Ticarcillin/Clavulanate ( <i>Timentin</i> )                | 3.1           |              | 6                           | 8 (CICr<30)              | 12         |  |  |  |  |  |
| Trimethoprim/Sulfamethoxazole (Bactrim)                    | 2 - 2.5       | 3.75 - 5     | 6                           | 8-12                     | 12-24      |  |  |  |  |  |
| Vancomycin   | 1             |              | 12                          | 24 (CICr<50)             | 168 (1 wk) |  |  |  |  |  |

CICr calculated by: (140-age) x (Ideal wt in kg.) (Multiply result by 0.85 for females (72) x (SeCr)

#### Legend:

CAP = Community Acquired Pneumonia HAP = Hospital Acquired Pneumonia MIC = Minimal Inhibitory Concentration CICr = Creatinine Clearance

SeCr = Serum Creatinine

**NEW / OTHER AGENTS** 

- 1. Cefepime: this 4th generation cephalosporin covers a wider spectrum than other cephalosporins. Its gram negative activity is comparable to ceftazidime but also includes Enterobacter spp., and its gram positive activity has been compared to ceftriaxone. Its anaerobic activity is weak especially against B. fragilis.
- 2. Levofloxacin: this 3rd generation fluoro-quinolone is indicated for the treatment of mild to moderate infections due to many gram positive, gram negative and atypical organisms. It is marketed for use in CAP and other moderate infections. Based on MIC, its activity is less against Pseudomonas than ciprofloxacin.
- 3. Aztreonam: this monobactam is mainly indicated for the treatment of gram negative infections in patients allergic to beta-lactam antibiotics. Its spectrum is comparable to an aminoglycoside and may be used in situations where an aminoglycoside is considered risky. When combined, a drug with a different mechanism of action should be used.
- 4. Quinupristin / Dalfopristin (Synercid): this streptogramin combination antibiotic is bacteriostatic against E faecium and bactericidal against methicillinsusceptible and methicillin-resistant Staphylococci. The drug is ineffective against E fecalis. Synercid should be reserved for cases of resistant gram positive infections, including VRE and MRSA. The drug is cleared primarily via biliary/fecal elimination, so dose adjustment is not recommended in renal dysfunction. Synercid is a major inhibitor of the cytochrome P450-3A4 isoenzyme and interactions should be expected with drugs metabolized via this pathway.
- 5. Linezolid (Zyvoxx): this oxalodinone antibiotic is bacteriostatic against Enterococci and Staphylococci, and bactericidal against Streptococci. Linezolid is 100% orally bioavailable and is marketed in IV and PO formulations. The drug is primarily cleared via hepatic metabolism, and while renal dysfunction does not affect the parent drug, its metabolites may accumulate in such patients. Linezolid should be reserved for resistant organisms such as VRE and MRSA.

YOUR HOSPITAL WASHINGTON, D.C.

## SYSTEMIC ANTIBIOTIC SUSCEPTIBILITY REPORT

### URINE

Compiled under the direction of:

# Lewis W. Marshall, M.D. Section of Infectious Disease

By

Mae Cundiff, CIC
Infection Control Coordinator

&

Laura Bunner, RN, CIC Infection Control Practioner

Zamir Shah, Pharm.D.
Pharmacy Clinical Coordinator

Data provided by
Mona Notghi, MT, (ASCP)

Clinical Microbiology

Richard B. Clark, Ph.D.

Vice President, Microbiology/Virology American Medical Laboratories, Inc. (AML)

January 1, 2000 thru December 31, 2000

| CDC Vancomycin Usage Guidelines  |   | Xxxxx Hospital<br>Washington, D.C.   | PERCENT SUSCEPTIBLE |             |               |                           |            |            |              |             |                       |            |                        |                           |           |            |             |                      |               |            |                                 |              |          |            |             |
|--|---|--|---------------------|-------------|---------------|---------------------------|------------|------------|--------------|-------------|-----------------------|------------|------------------------|---------------------------|-----------|------------|-------------|----------------------|---------------|------------|---------------------------------|--------------|----------|------------|-------------|
| <ol> <li>For treatment of infections caused by beta-lactam resistant organisms.</li> <li>For treatment of gram positive infections in patients with serious beta-lactam allergies.</li> <li>For treatment of antibiotic induced colitis which is unresponsive to metronidazole.</li> <li>AHA recommended andocarditis prophylaxis in high risk patients.</li> <li>As prophylaxis for major surgical procedures involving prosthetics.</li> </ol>                     |   | Antibiotic Susceptibility Report Urine 1/1/2000 to 12/31/2000 MICROORGANISMS | Number of Urine     | Norfloxacin | Nitrofurantim | Amoxicillin / Clavulanate | Vancomycin | Penicillin | Erythromycin | Clindamycin | Oxacillin / Nafcillin | Ampicillin | Ampicillin / Sulbactam | Ticarcillin / Clavulanate | Cefazolin | Cefotaxime | Ceftazidime | mipenem / Cilastatin | Ciprofloxacin | Gentamicin | Trimethoprim / Sulfamethoxazole | Tetracycline | Rifampin | Tobramycin | Ceftriaxone |
| drug will be dispensed. Proof of appropriate indication is needed for continued dispensing.  | ŀ | Staphyloccus aureus  | 58                  | 35          | 91            | 43                        | 100        | 6          | 33           | 55          | 43                    |            |                        |                           | 41        |            |             |                      | 38            | 81         | 88                              |              | ш.       |            |             |
| MICROBIOLOGY SENSITIVITY REQUESTS Cefepime, Levofloxacin* & Aztreonam are not available on the Rapid Microscan Panel. Microorganisms can be tested against these antibiotics, but require an   |   | Staphyloccus coagulase negative  | 32                  | 20          | 91            | 25                        | 100        | 6          | 35           | 66          | 25                    |            |                        |                           | 25        |            |             |                      | 19            | 50         | 71                              |              |          |            |             |
| additional 24-72 hrs for lab processing.   |   | Enterococcus sps.  | 303                 | 56          | 94            |                           | 94         | 90         | 17           |             |                       | 94         |                        |                           |           |            |             |                      | 53            |            |                                 | 35           |          |            |             |
| Request additional antibiotics at culture & sensitivity request time. Rapid Panel will be reported at normal time;   |   | Escherichia coli   | 733                 | 92          | 98            |                           |            |            |              |             |                       | 58         | 58                     | 93                        | 88        | 98         |             | 96                   | 88            | 92         | 80                              | 72           |          |            | 96          |
| additional antibiotics reported 24 hrs later. Microorganisms are kept in lab for   |   | Klebsiella pneumoniae  | 166                 | 94          | 88            |                           |            |            |              |             |                       | 4          | 42                     | 95                        | 91        | 91         |             | 100                  | 92            | 99         | 89                              | 70           |          |            | 99          |
| 12 hrs (for sensitivity reporting) and then discarded (usually by 10am next day). All efforts will be made to honor antibiotics requests submitted after Rapid Microscan Panel has been reported.  ** Gentamicin is 1st choice (due to susceptibility patterns + economics) unless C+S dictates otherwise.  *** Piperacillin is not on formulary; Piperacillin / Tazobactam (Zosyn) are & have broader spectrum.  ** See Back panel for more antibiotic information. |   | Klebsiella oxytoca   | 11                  | 100         | 100           |                           |            |            |              |             |                       | 9          | 18                     | 73                        | 36        | 99         |             | 100                  | 100           | 91         | 91                              | 100          |          |            | 91          |
|  |   | Enterobactercloacae  | 22                  | 86          | 86            |                           |            |            |              |             |                       | 0          | 0                      | 68                        | 0         | 68         | 64          | 95                   | 82            | 91         | 86                              | 68           |          |            | 68          |
|  |   | Enterobacter aerogenes   | 13                  | 85          | 77            |                           |            |            |              |             |                       | 8          | 15                     | 92                        | 69        | 92         | 92          | 100                  | 85            | 100        | 85                              | 85           |          |            | 92          |
|  | F | Pseudomonas aeruginosa   | 97                  | 48          |               |                           |            |            |              |             |                       |            |                        | 62                        |           | 9          | 67          | 82                   | 48            | 60         |                                 |              |          | 86         | 14          |

8850126 Rev 04/01 2000 Final Non-Urine\_INFECTION CONTROL Page 2 of 2